

AMENDMENTS

IN THE CLAIMS:

Please amend Claim 19 as indicated in Appendix A. The amended Claim reads as follows:

19. (Amended) A unit dosage composition for administration to a human patient, comprising a liquid suspension of cellular material including from about 10,000 to 10,000,000 apoptotic cells and/or apoptotic bodies per kilogram of patient body weight.

Please add new Claims 47-52. The new claims are as follows:

47. (New) The unit dosage composition of Claim 19, wherein the dosage contains from about 500,000 to about 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patent.

48. (New) The unit dosage composition of Claim 47, wherein the dosage contains from about 1,500,000 to about 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patent.

49. (New) The composition of Claim 16, wherein the apoptotic bodies and/or apoptotic cells are in a liquid suspension along with viable cells.

50. (New) The composition of claim 16, wherein the apoptotic bodies and/or apoptotic cells are derived from extracorporeal treatment of human blood cells.

51. (New) The composition of Claim 50, wherein the apoptotic bodies and/or apoptotic cells are derived from established cultured cell lines.

52. (New) The composition of Claim 50, wherein the human blood cells are white blood cells.